Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorChinese University of Hong Kong
About this trial
Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainstay of treatment. However, patients develop opioid-related adverse effects. EUS-guided celiac plexus neurolysis (CPN) and celiac ganglion neurolysis (CGN) has been shown to provide high efficacy for pain control. The optimal timing, however, is in debate.
Eligibility criteria
Qualifiers
Age >= 18 years old
Diagnosed to have inoperable pancreatic cancer
Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS >= 3
Karnofsky performance status >= 60
Disqualifiers
Allergy to bupivacaine, or alcohol
Potentially operable after neoadjuvant therapy
Expected survival of less than 3 months
Patient who is already on opioids for pain control
Trial design
Treatments tested in this trial
- EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis
Treatment groups
94 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov